N/A N=51 Smoking Cessation E-Visit
Smoking
Primary: Number of Participants Who Utilized Smoking Cessation Treatment — 15; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=315 This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
Heart Failure
Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the Distance Walked in 6 Minutes in Standardised Conditions (6MWTD) — 5.0; 10.0 Meter (m) — p=0.3660
Phase 3 N=450 Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC
NSCLC
Primary: Objective Response Rate — 46.4; 44.3 percentage of participants
N/A N=48 A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users
Microbicide Delivery System Acceptability
Primary: User Sensory Perception & Experience (USPE; Perceptibility) Scale Item Means — 3.64; 3.86; 4.35; 3.83 units on a scale
Phase 3 N=34 Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea
Advanced Cancers
Primary: Modified Dyspnea Borg Scale (Dyspnea Intensity) — -1.4; -0.5 score on a scale
Phase 2 N=136 A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Overall Response Rate Per RECIST Version 1.1 (Part 2) — 25; 7 Participants
Phase 4 N=60 A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery
Cataracts
Primary: Number of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days — 18; 28 Participants
Phase 2 N=107 CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
Candidemia · Mycoses · Fungal Infection
Primary: Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] — 71; 49; 55 Participants
Phase 1 N=57 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy
Healthy Participants · Narcolepsy
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 1; 0; 2; 4 Participants
Phase 3 N=6,564 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Peripheral Artery Disease
Primary: Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major…
Phase 2 N=1 Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome
Cancer · Skin Fibroblasts · Muscle Weakness
Primary: Change in PCr Recovery Tc Measurement From Baseline to 12 Week NR Supplementation Using the 31P-MRS Skeletal Muscle Submaximal Exercise. — 60; 73 Seconds
Phase 2 N=130 Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
Diabetic Macular Edema
Primary: BCVA — 0.8; -0.3; -1.8 Letters
N/A N=14 Study to Evaluate the Safety and Initial Effectiveness of the Sinusway™ for Endoscopy of Sinuses in Conjunction With BSD
Sinusitis
Primary: Number of Adverse Device Effects — 0 events
N/A N=15 An Open-Label, Multi-Center, Clinical Study Evaluating the Effect of the NDE L68 StableFit® Punctal Plug on the Tear Lake
Dry Eye Syndromes
Primary: Investigators' Evaluation of the Tear Lake; Comparison of Baseline Result to 7 Days — 129 mean percent change from baseline
Phase 2 N=116 Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
Primary: Participants With a Response — 4; 9; 16; 2 participants